查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1425004

膀胱癌治療和診斷市場，按診斷、癌症類型、國家和地區 - 2023-2030 年行業分析、市場規模、市場佔有率和預測

Bladder Cancer Therapeutics and Diagnostics Market, By Diagnostic, By Cancer Type, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 289 Pages | 商品交期: 2-3個工作天內

價格

報告要點

2022年膀胱癌治療和診斷市場規模為 37.942 億美元，2023年至2030年複合CAGR為 5.7%。

膀胱癌治療與診斷市場-市場動態

人們對膀胱疾病和可用療法的認知不斷提高，醫療保健支出不斷增加以及膀胱癌負擔的增加預計將推動市場需求

在人們對膀胱疾病和可用療法的認知不斷提高，醫療保健支出不斷擴大以及膀胱癌負擔日益加重等因素的推動下，膀胱癌治療和診斷市場有望快速成長。例如，2022年 3月，世界膀胱癌患者聯盟宣布了膀胱癌意識「不要變紅」主題，以提高對警告訊號和症狀的認知，強調早期檢測對於提高長期生存和品質的重要性的生活。此外，全球膀胱癌盛行率呈上升趨勢，根據《2020年全球癌症觀察站統計》，膀胱癌位居全球十大高發生癌症。同一份報告指出，2020年膀胱癌發生率已位居全球前10位。估計全球有 573,278 例膀胱癌新病例和 1,414,259 例前列腺癌新病例。全球癌症的高發生率是市場的重要驅動力。

膀胱癌治療和診斷市場 - 關鍵見解

根據研究分析師的分析，預計全球膀胱癌治療和診斷市場在預測期內（2023-2030）每年將以 5.7%左右的CAGR成長

由於人們對膀胱疾病和可用療法的認知不斷提高，醫療保健支出不斷擴大以及膀胱癌負擔日益加重，膀胱癌治療和診斷市場預計將以顯著的速度成長

根據 Diagnostic，膀胱鏡檢查領域預計在2022年顯示最大的市場佔有率

根據癌症類型，移行細胞膀胱癌是2022年的主要細分市場

依地區分類，北美是2022年的主要收入來源

膀胱癌治療與診斷市場細分分析：

全球膀胱癌治療和診斷市場根據診斷、癌症類型和地區進行細分。

根據診斷，市場分為四個部分：膀胱鏡檢查、膀胱超音波、尿液分析、其他診斷。膀胱鏡檢查部門產生了最高的收入，預計在整個預測期內將保持領先。膀胱鏡檢查是一種使用插入尿道的專用內視鏡觀察膀胱和尿道內部的手術，預計將成為預測期內研究市場的主導部分。這種具有成本效益的方法是由越來越多的採用，膀胱癌盛行率的上升以及主要市場參與者推出的產品所推動的。

市場依癌症類型分為三個部分：移行細胞膀胱癌、鱗狀細胞膀胱癌、其他癌症類型。預計到2030年，移行細胞膀胱癌細分市場將在全球膀胱癌診斷市場中佔據重要佔有率，這主要是由於移行細胞膀胱癌的高發生率。

膀胱癌治療與診斷市場 - 地理洞察

從地理來看，該市場廣泛分佈於北美、拉丁美洲、歐洲、亞太、中東和非洲地區。這些區域根據開展業務的國家進一步分類。由於癌症盛行率上升，預計北美將在預測期內主導市場。例如，根據美國癌症協會2022年1月的估計，2022年美國將新增約81,180例膀胱癌病例，其中男性61,700例，女性19,480例。

膀胱癌治療與診斷市場-競爭格局：

在膀胱癌治療和診斷領域，各公司積極研究和開發創新方法。在治療學中，一個值得注意的焦點是標靶治療（特別是免疫療法）的進步，以提高膀胱癌的治療效果。免疫檢查點抑制劑，例如pembrolizumab和atezolizumab等藥物，已獲得針對特定膀胱癌類型的批准，並且進行的研究日益擴大治療選擇的範圍。此外，該公司致力於探索有助於早期檢測、預後和治療反應評估的新型生物標記。這些生物標記可以幫助完善診斷方法並指導更個人化的治療介入措施，有可能改善患者的治療結果並減輕膀胱癌的整體負擔。該領域的公司致力於全面解決與膀胱癌相關的挑戰，從早期診斷到創新治療方式，最終目標是提高患者護理和存活率。

最近的發展：

2022年7月，美國食品和癌症類型管理局（FDA）同意審查ImmunityBio 的N-803 生物製品許可診斷（BLA），這可能使患有或不患有Ta 或T1 疾病的非肌肉層浸潤性膀胱癌症患者受益（NMIBC）原位癌（CIS）。

目錄

第1章 膀胱癌治療與診斷市場概述

  • 研究範圍
  • 市場預估年份

第2章 執行摘要

  • 市場摘要
    • 按診斷分類的膀胱癌治療與診斷市場摘要
    • 按癌症類型分類的膀胱癌治療和診斷市場摘要
    • 依國家分類的膀胱癌治療和診斷市場摘要
    • 依地區分類的膀胱癌治療和診斷市場摘要
  • 競爭洞察

第3章 膀胱癌治療和診斷主要市場趨勢

  • 膀胱癌治療與診斷市場促進因素
    • 市場促進因素的影響分析
  • 膀胱癌治療與診斷市場限制
    • 市場限制影響分析
  • 膀胱癌治療和診斷市場機會
  • 膀胱癌治療與診斷市場未來趨勢

第4章 膀胱癌治療與診斷產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章 膀胱癌治療與診斷市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第6章 膀胱癌治療與診斷市場格局

  • 2022年膀胱癌治療與診斷市佔率分析
  • 細分資料：按主要製造商
    • 既有參與者分析
    • 新興參與者分析

第7章 膀胱癌治療與診斷市場 - 按診斷

  • 概述
    • 細分市場佔有率分析（按診斷）
    • 膀胱鏡檢查
    • 膀胱超音波檢查
    • 尿液分析
    • 其他診斷

第8章 膀胱癌治療和診斷市場 - 按癌症類型

  • 概述
    • 按癌症類型分類的細分市場佔有率分析
    • 移行細胞膀胱癌
    • 鱗狀細胞膀胱癌
    • 其他癌症類型

第9章 膀胱癌治療和診斷市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美膀胱癌治療和診斷主要製造商
    • 北美市場規模和預測（依國家）
    • 北美市場規模和預測（依診斷）
    • 北美市場規模和預測（按癌症類型）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲膀胱癌治療和診斷主要製造商
    • 歐洲市場規模和預測（依國家）
    • 歐洲市場規模和預測（依診斷）
    • 歐洲市場規模和預測（按癌症類型）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區（APAC）
    • 概述
    • 亞太地區膀胱癌治療和診斷主要製造商
    • 亞太地區市場規模與預測（依國家）
    • 亞太地區市場規模和預測（依診斷）
    • 亞太地區市場規模和預測（按癌症類型）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲膀胱癌治療和診斷主要製造商
    • 拉丁美洲市場規模與預測（依國家）
    • 拉丁美洲市場規模和預測（依診斷）
    • 拉丁美洲市場規模與預測（按癌症類型）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲膀胱癌治療和診斷主要製造商
    • 中東和非洲市場規模及預測（依國家）
    • 中東和非洲市場規模及預測（依診斷）
    • 中東和非洲市場規模及預測（按癌症類型）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA的其他地區

第10章 主要供應商分析 - 膀胱癌治療與診斷產業

  • 競爭儀表板
  • 公司簡介
    • AstraZeneca
    • Bristol-Myers Squibb Company
    • Lilly
    • F. Hoffmann-La Roche Ltd
    • GSK plc
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • Endo Pharmaceuticals Inc.
    • Johnson & Johnson Services

第11章 360 度分析師視角

第12章 附錄

  • 研究方法論
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
Product Code: ANV2204

REPORT HIGHLIGHT

Bladder Cancer Therapeutics and Diagnostics Market size was valued at USD 3,794.2 Million in 2022, expanding at a CAGR of 5.7% from 2023 to 2030.

Acute lymphocytic/lymphoblastic leukemia is a cancer type originating from immature lymphocytes. The term "acute" denotes its rapid progression and spread throughout the body, originating in the bone marrow and swiftly infiltrating other vital organs like the liver, spleen, lymph nodes, central nervous system, and bloodstream. Symptoms may include fatigue, pallor, easy bruising, gum and nosebleeds, weight loss, shortness of breath, and loss of appetite. Multiple therapeutic approaches, including chemotherapy, are utilized in ALL treatment.

Bladder Cancer Therapeutics and Diagnostics Market- Market Dynamics

Increasing awareness of bladder diseases and available therapies, expanding healthcare expenditure, and the mounting burden of bladder cancer is expected to propel the market demand

The bladder cancer therapeutics and diagnostics market is poised for rapid growth, fueled by factors such as increasing awareness of bladder diseases and available therapies, expanding healthcare expenditure, and the mounting burden of bladder cancer. In March 2022, for example, the World Bladder Cancer Patient Coalition declared the 'Don't Go Red' theme for Bladder Cancer Awareness to raise awareness of warning signs and symptoms, underscoring the importance of early detection in enhancing long-term survival and quality of life. Furthermore, the global prevalence of bladder cancer is on the rise, with bladder cancer ranking among the top 10 high-incidence cancers worldwide according to the Global Cancer Observatory Statistics 2020. In the same report, it was noted that in 2020, there were an estimated 573,278 new cases of bladder cancer and 1,414,259 cases of prostate cancer worldwide. This high incidence of cancer globally is a significant driver for the market.

Bladder Cancer Therapeutics and Diagnostics Market- Key Insights

As per the analysis shared by our research analyst, the global Bladder Cancer Therapeutics and Diagnostics Market is estimated to grow annually at a CAGR of around 5.7% over the forecast period (2023-2030)

The Bladder Cancer Therapeutics and Diagnostics Market is projected to grow at a significant rate driven by increasing awareness of bladder diseases and available therapies, expanding healthcare expenditure, and the mounting burden of bladder cancer

Based on Diagnostic, the Cystoscopy segment was predicted to show maximum market share in the year 2022

Based on Cancer Type, Transitional Cell Bladder Cancer was the leading Segment in 2022

On the basis of region, North America was the leading revenue generator in 2022

Bladder Cancer Therapeutics and Diagnostics Market- Segmentation Analysis:

The Global Bladder Cancer Therapeutics and Diagnostics Market is segmented on the basis of Diagnostic, By Cancer Type, and Region.

Based on the Diagnostic, the market is divided into four segments: Cystoscopy, Bladder Ultrasound, Urinalysis, Other Diagnostics. The Cystoscopy segment generated the highest revenue, and it is expected to maintain its leading position throughout the forecast period. Cystoscopy, a procedure for visualizing the interior of the bladder and urethra using a specialized endoscope inserted through the urethra, is projected to be the dominant segment in the studied market during the forecast period. This cost-effective method is driven by increasing adoption, the rising prevalence of bladder cancer, and product launches by key market players.

The market is categorized by Cancer Type into three segments: Transitional Cell Bladder Cancer, Squamous Cell Bladder Cancer, Other Cancer Types. The transitional cell bladder cancer segment is expected to hold a significant share of the global bladder cancer diagnostics market by 2030, primarily due to the high incidence of transitional cell bladder cancer.

Bladder Cancer Therapeutics and Diagnostics Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the market during the forecast period owing to the rising prevalence of cancer. For instance, as to the January 2022 estimates from the American Cancer Society, about 81,180 new cases of bladder cancer would occur in the United States year 2022, with 61,700 cases in men and 19,480 cases in women.

Bladder Cancer Therapeutics and Diagnostics Market- Competitive Landscape:

In the realm of bladder cancer therapeutics and diagnostics, companies are fervently researching and developing innovative approaches. In therapeutics, a notable focus is on the advancement of targeted therapies, particularly immunotherapies, to enhance bladder cancer treatment outcomes. Immune checkpoint inhibitors, exemplified by drugs like pembrolizumab and atezolizumab, have secured approvals for specific bladder cancer types, and ongoing investigations are expanding the repertoire of treatment options. Moreover, companies are dedicated to exploring novel biomarkers that can aid in early detection, prognosis, and treatment response assessment. These biomarkers can help refine diagnostic methods and guide more personalized therapeutic interventions, potentially improving patient outcomes and reducing the overall burden of bladder cancer. Companies in this space are committed to addressing the challenges associated with bladder cancer comprehensively, from early diagnosis to innovative treatment modalities, with the ultimate goal of enhancing patient care and survival rates.

Recent Developments:

In July 2022, the United States Food and Cancer Type Administration (FDA) agreed to review ImmunityBio's Biologics License Diagnostic (BLA) for N-803, which could benefit patients with or without Ta or T1 illness who have non-muscle-invasive bladder cancer (NMIBC) carcinoma in situ (CIS).

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BLADDER CANCER THERAPEUTICS AND DIAGNOSTICS MARKET KEY PLAYERS

  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Lilly
  • F. Hoffmann-La Roche Ltd
  • GSK plc
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Endo Pharmaceuticals Inc.
  • Johnson & Johnson Services

GLOBAL BLADDER CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTIC

  • Cystoscopy
  • Bladder Ultrasound
  • Urinalysis
  • Other Diagnostics

GLOBAL BLADDER CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CANCER TYPE

  • Transitional Cell Bladder Cancer
  • Squamous Cell Bladder Cancer
  • Other Cancer Types

GLOBAL BLADDER CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Bladder Cancer Therapeutics and Diagnostics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Bladder Cancer Therapeutics and Diagnostics Market Snippet by Diagnostics
    • 2.1.2. Bladder Cancer Therapeutics and Diagnostics Market Snippet by Cancer Type
    • 2.1.3. Bladder Cancer Therapeutics and Diagnostics Market Snippet by Country
    • 2.1.4. Bladder Cancer Therapeutics and Diagnostics Market Snippet by Region
  • 2.2. Competitive Insights

3. Bladder Cancer Therapeutics and Diagnostics Key Market Trends

  • 3.1. Bladder Cancer Therapeutics and Diagnostics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Bladder Cancer Therapeutics and Diagnostics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Bladder Cancer Therapeutics and Diagnostics Market Opportunities
  • 3.4. Bladder Cancer Therapeutics and Diagnostics Market Future Trends

4. Bladder Cancer Therapeutics and Diagnostics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Bladder Cancer Therapeutics and Diagnostics Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Bladder Cancer Therapeutics and Diagnostics Market Landscape

  • 6.1. Bladder Cancer Therapeutics and Diagnostics Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Bladder Cancer Therapeutics and Diagnostics Market - By Diagnostics

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Diagnostics, 2022 & 2030 (%)
    • 7.1.2. Cystoscopy
    • 7.1.3. Bladder Ultrasound
    • 7.1.4. Urinalysis
    • 7.1.5. Other Diagnostics

8. Bladder Cancer Therapeutics and Diagnostics Market - By Cancer Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Cancer Type, 2022 & 2030 (%)
    • 8.1.2. Transitional Cell Bladder Cancer
    • 8.1.3. Squamous Cell Bladder Cancer
    • 8.1.4. Other Cancer Types

9. Bladder Cancer Therapeutics and Diagnostics Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Bladder Cancer Therapeutics and Diagnostics Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.2.6. U.S.
      • 9.2.6.1. Overview
      • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.2.6.3. U.S. Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.2.6.4. U.S. Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.2.7. Canada
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.2.7.3. Canada Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.2.7.4. Canada Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Bladder Cancer Therapeutics and Diagnostics Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.6. Germany
      • 9.3.6.1. Overview
      • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.6.3. Germany Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.6.4. Germany Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.7. Italy
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.7.3. Italy Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.7.4. Italy Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.8. United Kingdom
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.8.3. United Kingdom Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.8.4. United Kingdom Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.9. France
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.9.3. France Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.9.4. France Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.10. Russia
      • 9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.10.2. Russia Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.10.3. Russia Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.11. Netherlands
      • 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.11.2. Netherlands Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.11.3. Netherlands Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.12. Sweden
      • 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.12.2. Sweden Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.12.3. Sweden Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.13. Poland
      • 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.13.2. Poland Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.13.3. Poland Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.14. Rest of Europe
      • 9.3.14.1. Overview
      • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.14.3. Rest of the Europe Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.14.4. Rest of the Europe Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Bladder Cancer Therapeutics and Diagnostics Key Manufacturers in Asia Pacific
    • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.4.4. Asia Pacific Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
    • 9.4.5. Asia Pacific Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.6. India
      • 9.4.6.1. Overview
      • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.6.3. India Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.6.4. India Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.7. China
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.7.3. China Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.7.4. China Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.8. Japan
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.8.3. Japan Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.8.4. Japan Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.9. South Korea
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.9.3. South Korea Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.9.4. South Korea Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.10. Australia
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.10.3. Australia Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.10.4. Australia Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.11. Thailand
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.11.3. Thailand Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.11.4. Thailand Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.12. Indonesia
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.12.3. Indonesia Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.12.4. Indonesia Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.13. Philippines
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.13.3. Philippines Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.13.4. Philippines Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.14. Rest of APAC
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.14.3. Rest of APAC Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.14.4. Rest of APAC Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
  • 9.5. Latin America
    • 9.5.1. Overview
    • 9.5.2. Bladder Cancer Therapeutics and Diagnostics Key Manufacturers in Latin America
    • 9.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.5.4. Latin America Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
    • 9.5.5. Latin America Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Overview
      • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.6.3. Brazil Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.5.6.4. Brazil Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.5.7. Mexico
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.7.3. Mexico Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.5.7.4. Mexico Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.5.8. Argentina
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.8.3. Argentina Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.5.8.4. Argentina Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.5.9. Colombia
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.9.3. Colombia Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.5.9.4. Colombia Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.5.10. Rest of LATAM
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.5.10.4. Rest of LATAM Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Overview
    • 9.6.2. Bladder Cancer Therapeutics and Diagnostics Key Manufacturers in Middle East and Africa
    • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.6.4. Middle East and Africa Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
    • 9.6.5. Middle East and Africa Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.6.6. Saudi Arabia
      • 9.6.6.1. Overview
      • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.6.7. United Arab Emirates
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.7.3. United Arab Emirates Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.6.7.4. United Arab Emirates Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.6.8. Israel
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.8.3. Israel Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.6.8.4. Israel Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.6.9. Turkey
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.9.3. Turkey Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.6.9.4. Turkey Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.6.10. Algeria
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.10.3. Algeria Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.6.10.4. Algeria Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.6.11. Egypt
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.11.3. Egypt Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.6.11.4. Egypt Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.6.12. Rest of MEA
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.12.3. Rest of MEA Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.6.12.4. Rest of MEA Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)

10. Key Vendor Analysis- Bladder Cancer Therapeutics and Diagnostics Industry

  • 10.1. Competitive Dashboard
  • 10.2. Company Profiles
    • 10.2.1. AstraZeneca
    • 10.2.2. Bristol-Myers Squibb Company
    • 10.2.3. Lilly
    • 10.2.4. F. Hoffmann-La Roche Ltd
    • 10.2.5. GSK plc
    • 10.2.6. Novartis AG
    • 10.2.7. Pfizer Inc.
    • 10.2.8. Sanofi
    • 10.2.9. Endo Pharmaceuticals Inc.
    • 10.2.10. Johnson & Johnson Services

11. 360 Degree Analyst View

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Bladder Cancer Therapeutics and Diagnostics Market: Diagnostics Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Diagnostics
  • TABLE Global Bladder Cancer Therapeutics and Diagnostics Market, by Diagnostics 2018-2030 (USD Million)
  • TABLE Bladder Cancer Therapeutics and Diagnostics Market: Cancer Type Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Cancer Type
  • TABLE Global Bladder Cancer Therapeutics and Diagnostics Market, by Cancer Type 2018-2030 (USD Million)
  • TABLE Bladder Cancer Therapeutics and Diagnostics Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Bladder Cancer Therapeutics and Diagnostics Market, by Region 2018-2030 (USD Million)
  • TABLE North America Bladder Cancer Therapeutics and Diagnostics Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Bladder Cancer Therapeutics and Diagnostics Market, by Diagnostics, 2018-2030 (USD Million)
  • TABLE North America Bladder Cancer Therapeutics and Diagnostics Market, by Cancer Type, 2018-2030 (USD Million)
  • TABLE Europe Bladder Cancer Therapeutics and Diagnostics Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Bladder Cancer Therapeutics and Diagnostics Market, by Diagnostics, 2018-2030 (USD Million)
  • TABLE Europe Bladder Cancer Therapeutics and Diagnostics Market, by Cancer Type, 2018-2030 (USD Million)
  • TABLE Asia Pacific Bladder Cancer Therapeutics and Diagnostics Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Bladder Cancer Therapeutics and Diagnostics Market, by Diagnostics, 2018-2030 (USD Million)
  • TABLE Asia Pacific Bladder Cancer Therapeutics and Diagnostics Market, by Cancer Type, 2018-2030 (USD Million)
  • TABLE Latin America Bladder Cancer Therapeutics and Diagnostics Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Bladder Cancer Therapeutics and Diagnostics Market, by Diagnostics, 2018-2030 (USD Million)
  • TABLE Latin America Bladder Cancer Therapeutics and Diagnostics Market, by Cancer Type, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Bladder Cancer Therapeutics and Diagnostics Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Bladder Cancer Therapeutics and Diagnostics Market, by Diagnostics, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Bladder Cancer Therapeutics and Diagnostics Market, by Cancer Type, 2018-2030 (USD Million)

List of Figures

  • FIGURE Bladder Cancer Therapeutics and Diagnostics Market Segmentation
  • FIGURE Market research methodology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2022
  • FIGURE Diagnostics segment market share analysis, 2022 & 2030
  • FIGURE Diagnostics segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Cancer Type segment market share analysis, 2022 & 2030
  • FIGURE Cancer Type segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Regional segment market share analysis, 2022 & 2030
  • FIGURE Regional segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE North America Bladder Cancer Therapeutics and Diagnostics Market share and leading players, 2022
  • FIGURE Europe Bladder Cancer Therapeutics and Diagnostics Market share and leading players, 2022
  • FIGURE Asia Pacific Bladder Cancer Therapeutics and Diagnostics Market share and leading players, 2022
  • FIGURE Latin America Bladder Cancer Therapeutics and Diagnostics Market share and leading players, 2022
  • FIGURE Middle East and Africa Bladder Cancer Therapeutics and Diagnostics Market share and leading players, 2022
  • FIGURE North America market share analysis by country, 2022
  • FIGURE U.S. Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Canada Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Europe Bladder Cancer Therapeutics and Diagnostics Market share analysis by country, 2022
  • FIGURE Germany Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Spain Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Italy Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE France Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE UK Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Russia Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Netherlands Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Sweden Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Poland Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of the Europe Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Asia Pacific Bladder Cancer Therapeutics and Diagnostics Market share analysis by country, 2022
  • FIGURE India Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE China Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Japan Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE South Korea Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Australia Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Thailand Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Indonesia Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Phillipines Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of APAC Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Bladder Cancer Therapeutics and Diagnostics Market share analysis by country, 2022
  • FIGURE Brazil Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Mexico Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Argentina Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Colombia Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of LATAM Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Bladder Cancer Therapeutics and Diagnostics Market share analysis by country, 2022
  • FIGURE Saudi Arabia Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE United Arab Emirates Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Israel Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Turkey Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Algeria Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Egypt Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of MEA Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)